Glaxo buys rights to experimental diabetes drug Drug maker GlaxoSmithKline, which has co-US headquarters in Philadelphia and Research Triangle Park, has acquired exclusive rights to a potential diabetes treatment in a deal that could be worth more than \$180 million. 
Is this a piece of news regarding world politics, sports, business, or science and technology? 